Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 10/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654429 | 1.00 | GCK (0.39) | GCKFFAR2SMN1; SMN2AHR | |
| SCHEMBL2656473 | 0.90 | GCK (0.38) | GCKFFAR2 | |
| SCHEMBL2656483 | 0.90 | GCK (0.38) | GCKFFAR2 | |
| SCHEMBL2654906 | 0.90 | GCK (0.37) | GCKFFAR2SMN1; SMN2 | |
| SCHEMBL2654909 | 0.90 | GCK (0.37) | GCKFFAR2SMN1; SMN2 | |
| SCHEMBL2655764 | 0.89 | GCK (0.41) | GCKFFAR2 | |
| SCHEMBL2655762 | 0.89 | GCK (0.41) | GCKFFAR2 | |
| SCHEMBL2655116 | 0.85 | GCK (0.55) | GCKSMN1; SMN2 | |
| SCHEMBL2655114 | 0.85 | GCK (0.55) | GCKSMN1; SMN2 | |
| SCHEMBL2653628 | 0.82 | GCK (0.46) | GCKFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262196-B2 | Tri(cyclo) substituted amide glucokinase activator compounds | PROSIDION LIMITED (GB) | 2007-08-28 | — | — | US | claimed |
| EP-1594863-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | claimed |
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004072066-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | claimed |
| US-7262196-B2 | Tri(cyclo) substituted amide glucokinase activator compounds | PROSIDION LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | GCKR, GCK, GALK1 | GCK 2/4885FFAR2 1377/4885SMN1; SMN2 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.